Država: Sjedinjene Američke Države
Jezik: engleski
Izvor: NLM (National Library of Medicine)
nitroglycerin (UNII: G59M7S0WS3) (nitroglycerin - UNII:G59M7S0WS3)
Wilshire Pharmaceuticals, Inc.
nitroglycerin
nitroglycerin 400 ug
PRESCRIPTION DRUG
New Drug Application
NITROGLYCERIN LINGUAL- NITROGLYCERIN SPRAY, METERED WILSHIRE PHARMACEUTICALS, INC. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE NITROGLYCERIN LINGUAL SPRAY SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR NITROGLYCERIN LINGUAL SPRAY. NITROGLYCERIN LINGUAL SPRAY INITIAL U.S. APPROVAL: 1997 INDICATIONS AND USAGE Nitroglycerin Lingual Spray is a nitrate vasodilator indicated for acute relief of an attack or prophylaxis of angina pectoris due to coronary artery disease (1). DOSAGE AND ADMINISTRATION At the onset of an attack, administer onto or under the tongue. Repeat every 5 minutes as needed (2.1). Do up to three metered sprays within a 15-minute period. If chest pain persists, advise prompt medical attention (2.1). May be used prophylactically 5 to 10 minutes prior to engaging in activities that might precipitate an acute attack (2.1). DOSAGE FORMS AND STRENGTHS Lingual spray, 400 mcg per spray, available in 60 or 200 metered sprays per container (3). CONTRAINDICATIONS Use of phosphodiesterase type 5 (PDE5) inhibitors, such as avanafil, sildenafil, tadalafil, or vardenafil, or soluble guanylate cyclase (sGC) stimulator (riociguat). (4.1) Severe anemia. (4.2) Increased intracranial pressure. (4.3) History of hypersensitivity to Nitroglycerin Lingual Spray or to other nitrates or nitrites or any excipient. (4.4) WARNINGS AND PRECAUTIONS Tolerance: Excessive use may lead to tolerance. (5.1) Hypotension: Severe hypotension may occur. (5.2) ADVERSE REACTIONS Most common adverse reactions occurring at a frequency greater than 2 % are headache, dizzinesss and paresthesia (6). TO REPORT SUSPECTED ADVERSE REACTIONS, CONTACT WILSHIRE PHARMACEUTICALS, INC. AT 1-877-495-6856 OR FDA AT 1-800-FDA-1088 OR WWW.FDA.GOV/MEDWATCH. DRUG INTERACTIONS Antihypertensives: Possible additive hypotensive effects. (7.2) Ergotamine: increased bioavailability of ergotamine. Avoid concomitant use (7.3) SEE 17 FOR PATIENT COUNSELING INFORMATION AND FDA-APPROVED PA Pročitajte cijeli dokument